Product Description
ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15468604/)
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous,Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Renal Cell Carcinoma|Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin|Sarcoma|Melanoma|Head and Neck Cancer
Phase 1: Glioblastoma|Vascular Cancer|Dyspnea|Constipation|Diarrhea|Headache|Kidney Diseases|Brain Cancer|Colorectal Cancer|Low Back Pain|Skin Cancer|Angina, Unstable|Angina, Stable|Asthenia|Myocardial Infarction|Abdominal Pain|Anemia|Small Cell Lung Cancer|Ovarian Cancer|Glioma|Anorexia|Breast Cancer|Edema|Non-Small-Cell Lung Cancer|Insomnia|Chest Pain|Peripheral Arterial Disease|Dizziness|Hypertension, Renal|Ischemic Attack, Transient
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Pro00008797 | P1 |
Completed |
Colorectal Cancer|Angina, Stable|Angina, Unstable|Low Back Pain|Asthenia|Breast Cancer|Anorexia|Glioma|Non-Small-Cell Lung Cancer|Dyspnea|Edema|Anemia|Ovarian Cancer|Small Cell Lung Cancer|Insomnia|Diarrhea|Headache|Kidney Diseases|Abdominal Pain|Vascular Cancer|Chest Pain|Myocardial Infarction|Skin Cancer|Peripheral Arterial Disease|Constipation|Hypertension, Renal|Dizziness|Ischemic Attack, Transient |
2013-02-01 |
2019-03-22 |
Treatments |
|
| UAB 0327 | P1 |
Completed |
Glioblastoma|Brain Cancer |
2008-07-01 |
2019-03-22 |
Treatments |
|
| NCT00113334 | P2 |
Completed |
Head and Neck Cancer |
2008-03-01 |
2019-03-21 |
Treatments |
|
| CDR0000582475 | P2 |
Completed |
Melanoma |
2005-06-01 |
2019-03-18 |
Treatments |
|
| M02-428 | P2 |
Completed |
Renal Cell Carcinoma |
None |
2019-03-21 |
Treatments |
|
| M02-429 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
None |
2019-03-21 |
Treatments |
|
| M02-457 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
None |
2019-03-21 |
Treatments |
|
| M02-534 | P2 |
Completed |
Sarcoma |
None |
2019-03-21 |
Treatments |